Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 8,600 shares, a drop of 86.8% from the January 15th total of 65,100 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is currently ∞ days.

Antibe Therapeutics Stock Performance

Shares of OTCMKTS:ATBPF remained flat at $0.22 during trading on Friday. Antibe Therapeutics has a fifty-two week low of $0.11 and a fifty-two week high of $0.89. The company has a market capitalization of $11.42 million, a price-to-earnings ratio of -0.86 and a beta of 0.51. The firm has a fifty day simple moving average of $0.22 and a 200 day simple moving average of $0.22.

About Antibe Therapeutics

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).